Denali Therapeutics Inc (DNLI) Looks Ready for Growth Despite -13.56% Change This Year

Denali Therapeutics Inc (NASDAQ: DNLI) is -13.56% lower on its value in year-to-date trading and has touched a low of $15.45 and a high of $33.31 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The DNLI stock was last observed hovering at around $18.05 in the last trading session, with the day’s gains setting it 0.5%.

Currently trading at $18.55, the stock is 8.86% and -2.52% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.37 million and changing 2.77% at the moment leaves the stock -21.02% off its SMA200. DNLI registered -38.23% loss for a year compared to 6-month loss of -23.03%. The firm has a 50-day simple moving average (SMA 50) of $4.43 and a 200-day simple moving average (SMA200) of -$10.00.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a -0.75% gain in the last 1 month and extending the period to 3 months gives it a 8.42%, and is 17.18% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.74% over the week and 4.77% over the month.

Profit margin for the company is -36.51%. Distance from 52-week low is 20.06% and -44.31% from its 52-week high. The company has generated returns on investments over the last 12 months (-10.68%).

Denali Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.8 with sales reaching $8.36M over the same period.The EPS is expected to grow by 60.16% this year, but quarterly earnings will post 203.70% year-over-year. Quarterly sales are estimated to shrink -18.70% in year-over-year returns.

Denali Therapeutics Inc (DNLI) Top Institutional Holders

300 institutions hold shares in Denali Therapeutics Inc (DNLI), with institutional investors hold 95.18% of the company’s shares. The shares outstanding are 135.97M, and float is at 109.44M with Short Float at 8.99%. Institutions hold 81.21% of the Float.

The top institutional shareholder in the company is Baillie Gifford and Company with over 14.84 million shares valued at $438.04 million. The investor’s holdings represent 10.80% of the DNLI Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 10.24 million shares valued at $302.27 million to account for 7.45% of the shares outstanding. The other top investors are Blackrock Inc. which holds 10.11 million shares representing 7.36% and valued at over $298.24 million, while Wellington Management Group, LLP holds 5.12% of the shares totaling 7.04 million with a market value of $207.7 million.

Denali Therapeutics Inc (DNLI) Insider Activity

A total of 12 insider transactions have happened at Denali Therapeutics Inc (DNLI) in the last six months, with sales accounting for 12 and purchases happening 0 times. The most recent transaction is an insider sale by SATO VICKI L,the company’sDirector. SEC filings show that SATO VICKI L sold 1,666 shares of the company’s common stock on Jan 16 at a price of $18.42 per share for a total of $30688.0. Following the sale, the insider now owns 0.12 million shares.

Denali Therapeutics Inc disclosed in a document filed with the SEC on Jan 10 that Ho Carole (Chief Medical Officer) sold a total of 4,668 shares of the company’s common stock. The trade occurred on Jan 10 and was made at $19.02 per share for $88785.0. Following the transaction, the insider now directly holds 0.15 million shares of the DNLI stock.

Still, SEC filings show that on Jan 09, Watts Ryan J. (President and CEO) disposed off 7,818 shares at an average price of $19.78 for $0.15 million. The insider now directly holds 2,268,363 shares of Denali Therapeutics Inc (DNLI).

Denali Therapeutics Inc (DNLI): Who are the competitors?

The company’s main competitors (and peers) include Pieris Pharmaceuticals Inc. (PIRS) that is trading -90.47% down over the past 12 months. Plandai Biotechnology Inc. (PLPL) that is -33.33% lower over the same period.